Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Recommendation of “Moderate Buy” by Analysts

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $42.4286.

DMRA has been the subject of a number of research reports. TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 target price on the stock. Royal Bank Of Canada began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of the stock. Ikarian Capital LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $6,574,000. Jain Global LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $2,774,000. Remedium Capital Partners LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $2,772,000. Boothbay Fund Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $2,204,000. Finally, Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $100,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Down 1.9%

Shares of NASDAQ DMRA opened at $28.00 on Tuesday. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The firm has a market cap of $1.72 billion, a PE ratio of -5.02 and a beta of 1.46. The business has a fifty day simple moving average of $24.38 and a two-hundred day simple moving average of $25.49.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, research analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.